Valery Attignon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valery Attignon has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Ivan Bièche
Department of Genetics, Institut Curie, Paris, France
77 shared publications - Jean-Charles Soria
Département de Médecine, SITEP; and
64 shared publications - Alain Morel
Institut de Cancérologie de l'Ouest, Angers, France
53 shared publications - Alexandra Jacquet
30Unicancer, Paris, France
53 shared publications - Alexis Benjamin Cortot
CNRS, Inserm, Institut Pasteur de Lille, UMR9020‐UMR1277‐Canther‐Cancer Heterogeneity, Plasticity and Resistance to Therapies, Univ. Lille CHU Lille Lille France
53 shared publications Alicia Tran-Dien
53 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure 4. Forest plot with subgroup analysis for PFS in substudy 2.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure 4. Forest plot with subgroup analysis for PFS in substudy 2.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Material SM1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary materials - substudy 1 statistical report
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material SM1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary materials - substudy 1 statistical report
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table TS1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Table S1. Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table TS1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Table S1. Representativeness of Study Participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure 2. Forest plot with subgroup analysis for PFS in substudy 1.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure 2. Forest plot with subgroup analysis for PFS in substudy 1.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure 3. Forest plot with subgroup analysis for OS in substudy 1.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure 3. Forest plot with subgroup analysis for OS in substudy 1.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure 5. Forest plot with subgroup analysis for OS in substudy 2.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure 5. Forest plot with subgroup analysis for OS in substudy 2.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure 1. Planned exploratory analyses by study drug for selumetinib, vistusertib and capivasertib.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure 1. Planned exploratory analyses by study drug for selumetinib, vistusertib and capivasertib.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Material SM2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary materials - substudy 2 statistical report
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material SM2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary materials - substudy 2 statistical report
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends SL1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure legends 1-5
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends SL1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
Supplementary Figure legends 1-5